Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

85,834 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Inhibition of lipocalin 2 impairs breast tumorigenesis and metastasis.
Leng X, Ding T, Lin H, Wang Y, Hu L, Hu J, Feig B, Zhang W, Pusztai L, Symmans WF, Wu Y, Arlinghaus RB. Leng X, et al. Among authors: wu y. Cancer Res. 2009 Nov 15;69(22):8579-84. doi: 10.1158/0008-5472.CAN-09-1934. Epub 2009 Nov 3. Cancer Res. 2009. PMID: 19887608
Profile of Ets gene expression in human breast carcinoma.
He J, Pan Y, Hu J, Albarracin C, Wu Y, Dai JL. He J, et al. Among authors: wu y. Cancer Biol Ther. 2007 Jan;6(1):76-82. doi: 10.4161/cbt.6.1.3551. Cancer Biol Ther. 2007. PMID: 17172821 Free article.
Loss of annexin A1 expression in breast cancer progression.
Cao Y, Li Y, Edelweiss M, Arun B, Rosen D, Resetkova E, Wu Y, Liu J, Sahin A, Albarracin CT. Cao Y, et al. Among authors: wu y. Appl Immunohistochem Mol Morphol. 2008 Dec;16(6):530-4. doi: 10.1097/PAI.0b013e31817432c3. Appl Immunohistochem Mol Morphol. 2008. PMID: 18776816
WITHDRAWN: Requirement of lipocalin 2 in breast cancer.
Leng X, Ding T, Lin H, Wang Y, Wu Y, Arlinghaus RB. Leng X, et al. Among authors: wu y. Adv Enzyme Regul. 2009 Nov 13. doi: 10.1016/j.advenzreg.2009.10.001. Online ahead of print. Adv Enzyme Regul. 2009. PMID: 19914274 No abstract available.
Loss of HER2 amplification following trastuzumab-based neoadjuvant systemic therapy and survival outcomes.
Mittendorf EA, Wu Y, Scaltriti M, Meric-Bernstam F, Hunt KK, Dawood S, Esteva FJ, Buzdar AU, Chen H, Eksambi S, Hortobagyi GN, Baselga J, Gonzalez-Angulo AM. Mittendorf EA, et al. Among authors: wu y. Clin Cancer Res. 2009 Dec 1;15(23):7381-8. doi: 10.1158/1078-0432.CCR-09-1735. Epub 2009 Nov 17. Clin Cancer Res. 2009. PMID: 19920100 Free PMC article.
85,834 results
You have reached the last available page of results. Please see the User Guide for more information.